Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 714-721

  Sabatier, R ^a,b   Eymard, J C ^a   Walz, J ^c   Deville, J L ^a   Narbonne, H ^d   Boher, J M ^a   Salem, N ^a   Marcy, M ^a   Brunelle, S ^a   Viens, P ^a,b,e   Bladou, F ^e,f   Gravis, G ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT JEAN GODINOT   (France)

^d TIMONE HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Dysthyroidism; Prognosis; Renal cell cancer; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; LEVOTHYROXINE; SORAFENIB; SUNITINIB; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; THYROID DISEASE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84857545717     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr275     Document Type: Article

References (31)

1. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010; 13: 1-14.
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
3. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
4. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
5. Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531-3534.
6. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17: 351-355.
7. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumours. Ann Intern Med 2006; 145: 660-664.
8. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
9. Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinibinduced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99: 448-454.
10. Hercbergs AA, Goyal LK, Suh JH et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003; 23: 617-626.
11. Cristofanilli M, Yamamura Y, Kau SW et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103: 1122-1128.
12. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 1041-1046.
13. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumour response. J Clin Oncol 1983; 1: 710-719.
14. Van Houwelingen HC, Putter H. Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukaemia data. Lifetime Data Anal 2008; 14: 447-463.
15. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
16. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
17. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
18. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease, scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238.
19. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672.
20. Atkins MB, Mier JW, Parkinson DR et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318: 1557-1563.
21. Weijl NI, Van der Harst D, Brand A et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11: 1376-1383.
22. Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ. Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 974-975.
23. Gharib H, Tuttle RM, Baskin HJ et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Thyroid 2005; 15: 24-28.
24. Kamba T, Tam BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: H560-H576.
25. Alexandrescu DT, Popoveniuc G, Farzanmehr H et al. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 2008; 18: 809-812.
26. Garfield D, Hercbergs A, Davis P. Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 975-976.
27. Davis PJ, Davis FB, Lin HY et al. Cell-surface receptor for thyroid hormone and tumour cell proliferation. Expert Rev Endocrinol Metab 2006; 1: 753-761.
28. Wolter P, Stefan C, Decallonne B et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell carcinoma. J Clin Oncol 2008; 26 (Suppl): 280s (Abstr 5126).
29. Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011; 117: 534-544.
30. Garfield DH, Wolter P, Schöffski P et al. Documentation of thyroid function in clinical studies with sunitinib; why does it matter? J Clin Oncol 2008; 26: 5131-5132.
31. Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol 2007; 4: 674-675.